Cancer

Vanderbilt-Ingram Cancer Center earns NCI Merit Award

Vanderbilt-Ingram Cancer Center has earned a Merit Extension Award from the National Cancer Institute in recognition of more than a decade of sustained exceptional progress.

Blane Hollingsworth, PhD, was the first patient at VUMC to undergo a liver transplant under the protocol for cholangiocarcinoma.

Multidisciplinary care crucial in guiding Vanderbilt employee’s bile duct cancer journey

Blane Hollingsworth became the first patient at Vanderbilt to undergo a liver transplant under the protocol for cholangiocarcinoma, or bile duct cancer.

x-ray of stomach

Study validates pyrvinium as treatment to prevent stomach cancer

A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.

The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

Being treated for childhood cancer set Jason Schwartz on the path to his life’s work: treating childhood cancer

Cancer at the age of 13 forced him to give up his dream of professional football. While undergoing treatment, he found a new dream.

Vivian Weiss, MD, PhD, center, George Xu, left, and Matthew Loberg led a multidisciplinary study that identified a molecular signature for aggressive thyroid cancer, which could help guide treatment approaches for patients. (photo by Susan Urmy)

Researchers discover molecular signature for aggressive thyroid cancer

A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.

1 5 6 7 8 9 69